NCT07798726ClinicalTrials.gov
TransCatheter Replacement Of the Mitral Valve With the Novel Cephea Mitral Valve System
Kurz gefasst
The objective of this clinical trial is to evaluate the safety and effectiveness of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease (MVD) or are deemed unsuitable for surgery and transcatheter repair.
Interventionell565 Teilnehmende gesucht1 Studienzentrum1 Land
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07798726Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 5 Tagen
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-09-01; recorded start 2026-10-21
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 85 other studies in this databaseCounted from the lead sponsor named in the record (Abbott Medical Devices)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 9 conditions.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Non-randomised allocation
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 565 participants (target), run at 1 site.
How this score is built
- Enrolment27/40
565 participants (target)
- Site count0/25
1 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 112 months
- Sponsor scale7/10
Abbott Medical Devices has led 86 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The objective of this clinical trial is to evaluate the safety and effectiveness of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease (MVD) or are deemed unsuitable for surgery and transcatheter repair.
Erkrankungen
- Mitral Valve Disease
- Mitral Annulus Calcification
- Mitral Regurgitation
- Mitral Stenosis
- Mitral Valve (MV) Regurgitation
- Mitral Valve Replacement
- Transcatheter Valve Replacement
- Mitral Valve Insufficiency
- Heart Valve Disease
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Nicht zutreffend |
| Zuteilung | Nicht randomisiert |
| Interventionsmodell | SINGLE_GROUP |
| Primäres Ziel | TREATMENT |
| Verblindung | NONE (0) |
| Teilnahme | 565 Teilnehmende gesucht |
Sponsor und Mitwirkende
- Abbott Medical Devices Sponsor
Studienarme und Interventionen
- Mitral Regurgitation CohortEXPERIMENTAL
Inclusive of subjects who have moderate-to-severe or severe Mitral Regurgitation
- Mitral Annular Calcification (MAC) CohortEXPERIMENTAL
Inclusive of subjects with mitral valve dysfunction associated with MAC
Interventionen
- Medizinprodukt Cephea Mitral Valve System
During the transcatheter mitral valve replacement procedure, the Cephea Mitral Valve will be placed via transseptal approach
Endpunkte
Primärer Endpunkt
Primary Effectiveness Endpoint
Freedom from all-cause mortality and heart failure hospitalization
Zeitrahmen 12 months post index procedure.
Primärer Endpunkt
Primary Safety Endpoint
Incidence rate of the composite event of cardiovascular death, stroke, life-threatening bleeding, valve thrombosis, or paravalvular leak with hemolysis.
Zeitrahmen 30 days post index procedure
Sekundärer Endpunkt
Change in mitral regurgitation severity from baseline as assessed by the echocardiography core laboratory.
Mitral regurgitation will be graded on a scale from None (least) to Grade IV (most).
Zeitrahmen 12 months post index procedure
Sekundärer Endpunkt
Change in Quality of Life from baseline as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score
The overall summary score can range from 0-100, with higher scores representing a better quality of life.
Zeitrahmen 12 months post index procedure
Sekundärer Endpunkt
Change in the New York Heart Association Functional Classification of at least one grade from baseline.
New York Heart Association (NYHA) Functional Classification places patients in one of four classes based on their physical activity limitations, with Class I representing the least severe symptoms and increasing classifications representing more severe symptoms. Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort
Zeitrahmen 12 months post index procedure
Daten
| Startdatum | 21. Oktober 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 31. Dezember 2031 (geschätzt) |
| Abschluss | 31. Dezember 2035 (geschätzt) |
| Erstveröffentlichung | 1. September 2026 (tatsächlich) |
| Zuletzt aktualisiert | 13. November 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | November 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
1 Studienzentrum rekrutiert
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Ascension Via Christi Hospitals Wichita | Wichita | Kansas | Rekrutiert |
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 13. November 2026
Status geändert
Status changed from Unknown to Recruiting
UNKNOWNRECRUITING
- 13. November 2026
Rekrutierung eröffnet
Recruitment opened
UNKNOWNRECRUITING
- 13. November 2026
Studienzentrum hinzugefügt
1 site added (1 total)
01